PriceTargets.com logo

MeiraGTx - MGTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.50
  • Forecasted Upside: 262.65%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$6.48 As of 11/15/2024 01:00 AM ET
▼ -0.16 (-2.41%)

This chart shows the closing price for MGTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MeiraGTx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MGTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MGTX

Analyst Price Target is $23.50
▲ +262.65% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for MeiraGTx in the last 3 months. The average price target is $23.50, with a high forecast of $36.00 and a low forecast of $11.00. The average price target represents a 262.65% upside from the last price of $6.48.

This chart shows the closing price for MGTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in MeiraGTx. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$9.00 ➝ $11.00
8/13/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$11.00 ➝ $9.00
7/31/2024Chardan CapitalReiterated RatingBuy ➝ Buy$36.00
3/15/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$11.00
8/11/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$13.00 ➝ $11.00
8/11/2023Chardan CapitalReiterated RatingBuy ➝ Buy$41.00
5/12/2023Piper SandlerLower Target$26.00 ➝ $25.00
3/16/2023Chardan CapitalLower TargetBuy$47.00 ➝ $41.00
3/15/2023Royal Bank of CanadaLower TargetOutperform$27.00 ➝ $22.00
8/12/2022Chardan CapitalBoost TargetBuy$46.00 ➝ $47.00
5/13/2022Chardan CapitalReiterated RatingBuy$46.00
5/13/2022BarclaysLower Target$32.00 ➝ $18.00
5/12/2022Piper SandlerLower Target$40.00 ➝ $30.00
10/21/2021Bank of AmericaReiterated RatingBuy$26.00
7/1/2021Chardan CapitalReiterated RatingBuy
5/13/2021Evercore ISIInitiated CoverageBuy$27.00
10/22/2020Royal Bank of CanadaInitiated CoverageOutperform$27.00
9/15/2020Bank of AmericaInitiated CoverageBuy$20.00
8/16/2020Chardan CapitalReiterated RatingBuy$45.00
7/17/2020Piper SandlerReiterated RatingBuy$40.00
7/17/2020Chardan CapitalReiterated RatingBuy$45.00
5/31/2020Chardan CapitalReiterated RatingBuy$45.00
5/9/2020Chardan CapitalReiterated RatingBuy$45.00
3/22/2020Chardan CapitalReiterated RatingBuy$45.00
3/2/2020Chardan CapitalReiterated RatingBuy$45.00
1/30/2020Chardan CapitalReiterated RatingBuy$45.00
12/16/2019Piper Sandler CompaniesReiterated RatingBuy$40.00
12/16/2019Chardan CapitalReiterated RatingBuy$45.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

-0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/21/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/19/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
MeiraGTx logo
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
Read More

Today's Range

Now: $6.48
Low: $6.36
High: $6.71

50 Day Range

MA: $5.13
Low: $4.02
High: $7.10

52 Week Range

Now: $6.48
Low: $3.85
High: $7.60

Volume

371,464 shs

Average Volume

353,487 shs

Market Capitalization

$506.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Frequently Asked Questions

What sell-side analysts currently cover shares of MeiraGTx?

The following sell-side analysts have issued reports on MeiraGTx in the last year: Chardan Capital, Royal Bank of Canada, and TheStreet.
View the latest analyst ratings for MGTX.

What is the current price target for MeiraGTx?

0 Wall Street analysts have set twelve-month price targets for MeiraGTx in the last year. Their average twelve-month price target is $23.50, suggesting a possible upside of 262.7%. Chardan Capital has the highest price target set, predicting MGTX will reach $36.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $11.00 for MeiraGTx in the next year.
View the latest price targets for MGTX.

What is the current consensus analyst rating for MeiraGTx?

MeiraGTx currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MGTX will outperform the market and that investors should add to their positions of MeiraGTx.
View the latest ratings for MGTX.

What other companies compete with MeiraGTx?

Other companies that are similar to MeiraGTx include Harpoon Therapeutics, Cellular Biomedicine Group, Voyager Therapeutics, Freeline Therapeutics and Intellia Therapeutics. Learn More about companies similar to MeiraGTx.

How do I contact MeiraGTx's investor relations team?

MeiraGTx's physical mailing address is 450 East 29thStreet 14thFloor, NEW YORK NY, 10016. The company's listed phone number is (646) 860-7985 and its investor relations email address is [email protected]. The official website for MeiraGTx is www.meiragtx.com. Learn More about contacing MeiraGTx investor relations.